McDermott Will & Schulte advised the founders of Excelya on Eurazeo's entry into the company's capital

"McDermott Will & Schulte advised Excelya founders François Moisson and Frédéric Paqueville on Eurazeo’s entry as a reference investor alongside management. The investment will support Excelya’s targeted external growth to accelerate its European expansion and pursue its ambition to become the leading clinical research partner for mid‑sized European pharmaceutical companies."

McDermott Will & Schulte advised Excelya founders François Moisson and Frédéric Paqueville in connection with Eurazeo’s entry into the company’s capital. Eurazeo has become a reference investor alongside Excelya's management team. Through this transaction, Excelya intends to accelerate its European expansion, notably by pursuing targeted external growth (acquisitions). The Group aims to become the European leader in clinical research, positioning itself as the preferred partner for mid‑sized European pharmaceutical laboratories. McDermott Will & Schulte represented Excelya founders François Moisson and Frédéric Paqueville with a team composed by: Corporate - Grégoire Andrieux, Partner - Côme Wirz, Counsel - Maud Moriceau, Associate Tax - Antoine Vergnat, Partner - Fanny Le Pogam, Associate Financing - Stanislas Chenu, Associate - Clarisse de Roux, Associate

McDermott Will & Schulte advised the founders of Excelya on Eurazeo's entry into the company's capital

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads